The Use of Stromal Vascular Fraction in the Treatment of Male Sexual Dysfunction: A Review of Preclinical and Clinical Studies.

Erectile Dysfunction Male Sexual Dysfunction Peyronie's Disease Stromal Vascular Fraction Tissue Regeneration

Journal

Sexual medicine reviews
ISSN: 2050-0521
Titre abrégé: Sex Med Rev
Pays: Netherlands
ID NLM: 101614773

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 22 01 2018
revised: 09 04 2018
accepted: 09 04 2018
pubmed: 2 7 2018
medline: 30 4 2019
entrez: 2 7 2018
Statut: ppublish

Résumé

Stem cell therapy using stromal vascular fraction (SVF) is a promising treatment modality. SVF is comprised of a mixture of adipose-derived stem cells, endothelial precursor cells, and immune modulatory cells that act synergistically to facilitate angiogenesis and epithelial cell differentiation. This makes SVF an attractive option for men's sexual disorders that require reconstitution of vasculature and endothelial lining, namely erectile dysfunction (ED) and Peyronie's disease (PD). The objective of this study was to compare and contrast the available literature regarding the use of SVF in the treatment of male sexual dysfunction. A literature review was performed in PubMed with the keywords "stromal vascular fraction" and/or "erectile dysfunction" and/or "Peyronie's disease" and/or "sexual dysfunction." The main outcome measure for preclinical studies was erectile function, as measured by changes in intracavernous pressures, and results of histopathologic analysis of corporal tissue. Clinical endpoint analysis in humans included various patient questionnaires. For ED, there were 5 preclinical studies included in the analysis, with 1 Phase 1 clinical trial in humans. Major limitations of both the preclinical and clinical studies included the absence of SVF component analysis, and short duration of follow-up. Despite a paucity of preclinical studies, there was a single clinical study assessing the efficacy of combination SVF and shock wave therapy in the treatment of PD. Limitations of this study included an absence of a control group and the use of subjective data. Preclinical and clinical data in the use of SVF for the treatment of male sexual dysfunction is deficient. Even though multiple medicinal disciplines are studying the use of SVF on a myriad of pathologies, further investigative work elucidating the mechanism and potential adverse effects of SVF need to be performed before clinical trials are undertaken. Haney NM, Gabrielson A, Kohn TP, Hellstrom WJG. The Use of Stromal Vascular Fraction in the Treatment of Male Sexual Dysfunction: A Review of Preclinical and Clinical Studies. Sex Med Rev 2019;7:313-320.

Identifiants

pubmed: 29960873
pii: S2050-0521(18)30054-4
doi: 10.1016/j.sxmr.2018.04.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

313-320

Informations de copyright

Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Nora M Haney (NM)

Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.

Andrew Gabrielson (A)

Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA.

Taylor P Kohn (TP)

Baylor College of Medicine, Department of Urology, Houston, TX, USA.

Wayne J G Hellstrom (WJG)

Tulane University School of Medicine, Department of Urology, New Orleans, LA, USA. Electronic address: whellst@tulane.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH